1354804-56-0

Basic information

• Product Name: 4-{2-[9-(2,4-difluorobenzyl)-5,6,8,9-tetrahydro-7H-pyrido[4',3':4,5]pyrrolo[2,3-b]pyridin-7-yl]-2-oxoethyl}bicyclo[2.2.2]octane-1-carboxylic acid
• Synonyms: 4-{2-[9-(2,4-difluorobenzyl)-5,6,8,9-tetrahydro-7H-pyrido[4',3':4,5]pyrrolo[2,3-b]pyridin-7-yl]-2-oxoethyl}bicyclo[2.2.2]octane-1-carboxylic acid
• CAS NO: 1354804-56-0
• Molecular Weight: 493.553
• Mol File: 1354804-56-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-{2-[9-(2,4-difluorobenzyl)-5,6,8,9-tetrahydro-7H-pyrido[4',3':4,5]pyrrolo[2,3-b]pyridin-7-yl]-2-oxoethyl}bicyclo[2.2.2]octane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{2-[9-(2,4-difluorobenzyl)-5,6,8,9-tetrahydro-7H-pyrido[4',3':4,5]pyrrolo[2,3-b]pyridin-7-yl]-2-oxoethyl}bicyclo[2.2.2]octane-1-carboxylic acid(1354804-56-0)
• EPA Substance Registry System: 4-{2-[9-(2,4-difluorobenzyl)-5,6,8,9-tetrahydro-7H-pyrido[4',3':4,5]pyrrolo[2,3-b]pyridin-7-yl]-2-oxoethyl}bicyclo[2.2.2]octane-1-carboxylic acid(1354804-56-0)

Safety Data

• Hazardous Substances Data: 1354804-56-0(Hazardous Substances Data)

Upstream product

• 161975-35-5 C₉H₁₃ClO₃ 
• 1354803-84-1 methyl cis-4-(diazoacetyl)cyclohexanecarboxylate 
• 1011-85-4 (1S,4S)-4-(methoxycarbonyl)cyclohexane-1-carboxylic acid 
• 23915-07-3 1-(bromomethyl)-2,4-difluorobenzene 
• 1354801-07-2 tert-butyl 5,6,8,9-tetrahydro-7H-pyrido[4’,3’:4,5]pyrrolo[2,3-b]pyridine-7-carboxylate 

Relevant articles and documents

ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model

Lysophosphatidic acid (LPA) is a bioactive lipid mediator that elicits a number of biological functions, including smooth muscle contraction, cell motility, proliferation, and morphological change. LPA is endogenously produced by autotaxin (ATX) from extracellular lysophosphatidylcholine (LPC) in plasma. Herein, we report our medicinal chemistry effort to identify a novel and highly potent ATX inhibitor, ONO-8430506 (20), with good oral availability. To enhance the enzymatic ATX inhibitory activity, we designed several compounds by structurally comparing our hit compound with the endogenous ligand LPC. Further optimization to improve the pharmacokinetic profile and enhance the ATX inhibitory activity in human plasma resulted in the identification of ONO-8430506 (20), which enhanced the antitumor effect of paclitaxel in a breast cancer model.